Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.59 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30253476 | 1.00 | PPARA (0.59) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL7172323 | 1.00 | PPARA (0.59) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL1562695 | 1.00 | PPARA (0.59) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL12292883 | 0.95 | PPARA (0.55) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL12294436 | 0.92 | CTSS (0.61) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL16478621 | 0.91 | ACE (0.55) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL16472131 | 0.91 | ACE (0.55) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL17949815 | 0.91 | ACE (0.55) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL12293283 | 0.90 | CTSK (0.52) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL1094804 | 0.90 | PPARA (0.57) | PPARASYKCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954987-A | Apoptosis bionic nano drug delivery carrier and preparation method and application thereof | 暨南大学 | 2025-05-09 | — | — | CN | claimed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIBRANT HOLDINGS LLC (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12454771-B2 | Substrates, peptide arrays, and methods | VIBRANT HOLDINGS LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250263365-A1 | O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-21 | — | — | US | disclosed |
| EP-3878836-B1 | O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-12312297-B2 | O-substituted serine derivative production method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-27 | — | — | US | disclosed |
| CN-119954987-A | Apoptosis bionic nano drug delivery carrier and preparation method and application thereof | 暨南大学 | 2025-05-09 | — | — | CN | disclosed |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| US-5175257-A | Radiolabeled proteins for diagnostic or therapeutic use | NEORX CORPORATION (US) | 1992-12-29 | — | — | US | disclosed |
| US-5117034-A | Phosphatidylserine derivatives | FUJI PHOTO FILM CO., LTD. (JP) | 1992-05-26 | — | — | US | disclosed |
| US-5112953-A | RADIOLABELED PROTEINS FOR DIAGNOSTIC OR THERAPEUTIC USE | NEORX CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0483732-A2 | Phosphorylating agent and method for forming phosphodiester bond using the same | FUJI PHOTO FILM CO., LTD. (JP) | 1992-05-06 | — | — | EP | disclosed |
| EP-0461245-A1 | RADIOLABELED PROTEINS FOR DIAGNOSTIC OR THERAPEUTIC USE | NEORX CORPORATION (US) | 1991-12-18 | — | — | EP | disclosed |
| EP-0274234-B1 | SPIRO-SUBSITUTED GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1991-09-11 | — | — | EP | disclosed |
| WO-1991009876-A1 | RADIOLABELED PROTEINS FOR DIAGNOSTIC OR THERAPEUTIC USE | NEORX CORPORATION (US) | 1991-07-11 | — | — | WO | disclosed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | disclosed |
| EP-0274234-A2 | Spiro-subsituted glutaramide diuretic agents | Pfizer Limited (GB) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIP, CALCB, SPPL2B | PPARA 3535/4885SYK 937/4885CTSS 254/4885 |
| US-20250263365-A1 | O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD | STS, SMOX, TST | PPARA 4142/4885SYK 534/4885CTSS 2594/4885 |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | PPARA 934/4885SYK 2298/4885CTSS 3550/4885 |
| US-12312297-B2 | O-substituted serine derivative production method | STS, SMOX, TST | PPARA 4142/4885SYK 534/4885CTSS 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.